We describe issues and outcomes in the development of a specialized, central institutional review board (IRB) for multicenter oncology protocols.
INTRODUCTION
regional, centralized Research Ethics Board (REB; Canadian terminology equivalent to IRB) was creThe research ethics oversight system in North ated to provide consistent, excellent, and efficient America does not optimally manage human particethics review and oversight of MCTs in the Cana ipant protection in multicenter trials (MCTs) [1] [2] [3] [4] By dian province of Ontario. failing to adapt to the growing MCT environment, the traditional research ethics system is fraught with Genesis of the Ontario Cancer Research redundancy, 3 in which multiple individual instituEthics Board tional review boards (IRBs) review the same reOntario, which has a population of more than search and use increasingly strained resources. 1 12 million and an area greater than 1,000,000 km 2 , Because of a 42% increase in the volume of studies delivers cancer treatment at 28 community and reviewed by IRBs during a 5-year period, the Office teaching hospitals, which includes 14 Integrated of the Inspector General (OIG) of Human Health Cancer Programs (ICPs) that provide specialized Services (HHS) describes the IRB system as "in jeoptreatment. The ICPs work together with their host ardy"; IRBs "review too much, too quickly, with too hospital and with Cancer Care Ontario, the provin little expertise." 1 For investigators and sponsors, IRB cial cancer agency that steers and coordinates Onreview has become a formidable barrier to the timely tario's cancer services and prevention efforts. initiation and conduction of MCTs. For IRBs, the Accordingly, Ontario was seen as an ideal setting in costs and workload are becoming unmanageable. A which to test the feasibility of a central IRB.
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There were four key motivations that fostered the establishment of a central, cancer-specific IRB in Ontario: (1) the need to provide excellent scrutiny of cancer clinical trials by creating an oncologyspecific IRB; excellence was a sine qua non for any success of the project; (2) the requirement to effect more timely and efficient ap proval of MCTs across multiple sites by centralizing the review pro cess; (3) the need to reduce duplication in the management of external serious adverse event (SAE) reporting; and (4) the potential that a central IRB would have more influence in dealing with sponsors in MCTs than individual, local IRBs.
In addition, the project could serve as a proof-of-concept of a central IRB in any discipline across any large geographic area.
The Ontario Cancer Research Ethics Board (OCREB) proposal was comprised of three key elements. The first was a desire for excel lence in terms of policies, procedures, and people. It was presumed that excellent, timely decision making on the part of OCREB was key to its success and that a well established, specialized, central IRB could provide more depth of scientific and clinical expertise than could most local IRBs. A second key element was that OCREB would have to continuously win the support of the institutions, because the use of OCREB (instead of the local IRB) would be voluntary and because the benefits of a central IRB model could only be realized with the partic ipation of a critical mass of sites. In particular, OCREB would have to win early adopters through the promotion of the potential long-term benefits of the model. The third element of the proposal was that the new IRB would have its own funding and would therefore not affect the existing financial arrangements of local institutions.
A consultative meeting was held with REB representatives and clinical trials managers from each cancer center. There was broad diversity in the perceived need for OCREB (from urgent to none). The potential barriers that were identified related to concerns about insti tutional risk and infringement on local REB jurisdiction.
The formal creation of OCREB stemmed from extensive provin cial and national consultation. Other models of central ethics review were researched, and legal opinion was obtained. OCREB was estab lished in compliance with applicable regulatory requirements and included medical and radiation oncologists; nurses with experience in oncology research; informed community members and/or cancer sur vivors; and members with expertise in research ethics and relevant law, including privacy legislation, pharmacy, epidemiology, biostatistics and other related disciplines when necessary (e.g., surgical oncology). Membership consisted of broad representation from across Ontario, and each institution was encouraged to select a local representative to serve on OCREB.
METHODS
Developing the OCREB Model
After completion of the organizational and developmental efforts, OCREB began reviewing protocols in January 2004. Initially, there were two options for OCREB review: facilitated review and board of record. In facili tated review, the local IRB remained the board of record and used OCREB's expert oncology review findings to assist in its own review. In the board-of record option, OCREB is registered under the institution's federal-wide assur ance, and OCREB contracts with the institution to serve as its IRB on a study-by-study basis for initial review and for ongoing oversight. The local IRB is not involved in the study when OCREB is the board of record. Before IRB review, the institution conducts an administrative review of the research to assess study impact, adequacy of local resources, investigator competence, and any other local issues.
Ultimately, the facilitated-review process was found to be unattractive, particularly by investigators and sponsors, as it delayed the review process by requiring an additional, sequential review layer. However, it proved valuable in that it introduced OCREB to clinical trial sites and allowed them to assess the quality of OCREB reviews. Sites that initially used the facilitated-review pro cess eventually moved to the board-of-record option. This experience is con sistent with the assessment of Enzle and Schmaltz, 6 who saw that a successful central IRB system "must avoid serial review processes while engendering trust by local institutional authorities and REBs."
RESULTS
In its first year of operation, OCREB met 12 times and reviewed 19 multicenter cancer protocols (Fig 1) : 11 clinical trials and eight re gional epidemiologic studies. In the five centers that used OCREB as their IRB of record, the average time from receipt of the protocol to OCREB approval was 29 days. Of note, two of five board-of-record centers initially restricted their use of OCREB to specific, cooperativegroup studies as a means of piloting OCREB.
By the end of its second full year of operation, the number of institutions that used OCREB increased to seven, and the number of new submissions increased by 64% to 31 (ie, 21 clinical trials and 11 epidemiologic or chart review studies). The average time from receipt of protocol to OCREB approval climbed to just greater than 3 months for the board-of-record option; the facilitated-review option was al ready falling out of favor. This increase in approval time can be attrib uted to delays in the receipt of investigator responses to the OCREB review letters, to delays in the receipt of regulatory documents re quired to issue approvals (eg, Health Canada "No Objection" Letters), and to incremental increases in the number of active studies that resulted in a cumulative increase in the OCREB administrative work load (eg, amendments and renewals that required full OCREB review, numerous external SAEs). The time from the receipt of protocol to approval remained constant in 2006 (mean, 70 business days), al though 38 of those days accounted for the average time spent waiting for investigator responses. By the end of 2006 (ie, year 3), 14 institutions had a formal relationship with OCREB, and two of the three centers that began with restricted use of OCREB had authorized the use of OCREB for any MCT, as decided locally on a study-by-study basis. There were 56 new submissions in 2006 (all but two were clinical trials), and nearly 90% of all trials submitted since OCREB's inception remained active.
The average number of participating centers per clinical trial remained constant at 1.4 for 2004, 2005 , and most of 2006, which is an indication that OCREB had not yet achieved a critical mass of institu tions that were participating in the same trials. Because many of the studies submitted to OCREB are leading-edge, early-phase, drug de velopment trials, the low number of centers per trial was expected. The advantage to accepting early phase trials despite the fewer centers is that Ontario then will have gained the experience that will attract the later-phase, follow-up trials. The number of centers per trial did in crease to 2.6 in the latter part of 2006, which brought the overall average for 2006 to 1.8 centers per trial (Fig 2) .
DISCUSSION
Multiple reviews by individual IRBs do not provide any clear advan tage compared with a central, expert review.
7 Studies that examined differences in responses among IRBs within the same protocol reveal an unexplained variation among IRBs and a costly process of review. No. No. of Centers man Research Protections reviewed a number of innovative models of IRB review, including three examples of central ethics review of MCTs. 2 The focus was on the improvement of the quality of review and on the reduction of an excessive IRB workload. The US Food and Drug Administration issued a guidance document on central ethics review of MCTs that particularly addressed efficiency and timeliness. 4 In addition, the US Office of Human Research Protection (OHRP) guidance document "IRB Knowledge of Local Research Context" contains alternative ways to incorporate knowledge of the local con text into the central IRB model. 16 Importantly, both the Canadian and US regulations and guidelines that govern research ethics allow for central ethics review. [17] [18] [19] There are already a number of precedents for central IRB review. [20] [21] [22] [23] One example is the Multi-Center Academic Clinical Re search Organization (MACRO), 20 a consortium of major academic health care centers with reciprocity agreements to facilitate ethical and administrative approval of MCTs that involve the five universities. Ethical approval at any one site constitutes ethical approval at all five. The proposal, although appealing in principle, has not succeeded in attracting many trials.
Another example is the National Cancer Institute Central IRB (NCI CIRB). 22 The NCI CIRB involves 263 participating adultoriented and 128 pediatric-oriented institutions. One review is done centrally for each study, and a facilitated review is conducted by the local IRB chair/subcommittee, which concentrates on local issues. The CIRB serves as the board of record and is responsible for the continu ing review and the subsequent amendments and SAEs. 24 The local IRB is responsible for the review of local SAEs and for the oversight of local conduct of the study. More than 116 phase III, adult, cooperative-group oncology protocols have been reviewed since January 2001. OCREB adopted a model that is similar but not identical to that of the NCI CIRB.
From the perspectives of quality and efficiency, a specialized central IRB intuitively makes sense. Specialization provides the exper tise required for complex reviews, and centralization promotes effi cient use of resources. In addition, conflicts-of-interest in supporting the work of the institution's own investigators is lessened or eliminat ed 3 ; the central IRB truly is at an arm's length from the institution.
At the outset, OCREB was rapidly adopted by nonacademic hospitals that had limited oncology-specific research ethics expertise. Subsequently, large nonacademic and small university hospitals fol lowed suit; a few large academic hospitals were testing the waters with a small number of trials. Large academic hospitals were the last to adopt OCREB, which perhaps reflected a greater satisfaction with their status quo.
During the first three years of operation, OCREB faced several challenges: (1) a substantial effort required to win support from each institution; (2) the adaptation and development of operational pro cesses specific to a central IRB model; (3) the recognition of the large cumulative workload for an oncology-specific IRB, and the provision of appropriate staffing levels; and (4) education and communication to assist institutions in adapting to different processes required with a central IRB model.
Presently, 14 of the 27 institutions that conduct oncology trials in Ontario have authorized a board-of-record relationship with OCREB and are actively using OCREB for multicenter cancer studies. Additional sites are planning to opt for this relationship, which is an indication that OCREB is fulfilling a need and is considered a central IRB model that works.
In conclusion, OCREB, functioning as a regional IRB, was iniwith a "U" are those for which no compensation was received; those relationships marked with a "C" were compensated. tially, there was considerable concern regarding the lack of jurisdiction OCREB is poised for substantial growth. OCREB will address its Other Remuneration: None internal procedures and will seek to improve its coordination with investigators and sponsors. OCREB will reach its full potential only when it is the board of record for a large number of sites per study. OCREB is working to improve the quality and efficiency of research ethics Conception and design: Raphael Saginur, Susan F. Dent, Lisa Schwartz,
